Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Collegium Pharmaceutical Inc    COLL

COLLEGIUM PHARMACEUTICAL INC (COLL)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/17/2018 04/18/2018 04/19/2018 04/20/2018 04/23/2018 Date
24.8(c) 24.89(c) 25.43(c) 24.67(c) 24.21(c) Last
468 495 487 216 582 004 245 840 184 617 Volume
+6.90% +0.36% +2.17% -2.99% -1.86% Change
More quotes
Financials (USD)
Sales 2018 297 M
EBIT 2018 5,40 M
Net income 2018 -26,5 M
Finance 2018 87,0 M
Yield 2018 -
Sales 2019 366 M
EBIT 2019 58,4 M
Net income 2019 27,6 M
Finance 2019 122 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019 31,37
EV / Sales2018 2,45x
EV / Sales2019 1,89x
Capitalization 815 M
More Financials
Company
Collegium Pharmaceutical, Inc. engages in the development and commercialization of next-generation, abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases.Its products include Xtampza ER, and ONSOLIS.Xtampza ER provides... 
Sector
Pharmaceuticals
Calendar
05/08 | 06:50pmPresentation
More about the company
Surperformance© ratings of Collegium Pharmaceutical I
Trading Rating : Investor Rating :
More Ratings
Latest news on COLLEGIUM PHARMACEUTICAL I
04/20Collegium to Host Conference Call to Discuss First Quarter 2018 Financial Res..
GL
04/04COLLEGIUM PHARMACEUTICAL : to Present at the H.C. Wainwright Global Life Science..
AQ
04/04Collegium to Present at the H.C. Wainwright Global Life Sciences Conference
GL
03/19COLLEGIUM PHARMACEUTICAL : Announces the Appointment of Shirley Kuhlmann as Gene..
AQ
03/16Collegium to Present at Upcoming Investor Conferences
GL
03/07COLLEGIUM PHARMACEUTICAL : Management's Discussion and Analysis of Financial Con..
AQ
03/07COLLEGIUM PHARMACEUTICAL : posts 4Q loss
AQ
03/07COLLEGIUM PHARMACEUTICAL, INC : Results of Operations and Financial Condition, F..
AQ
03/07COLLEGIUM PHARMACEUTICAL : Reports Fourth Quarter Financial Results and Provides..
AQ
03/07COLLEGIUM PHARMACEUTICAL INC : Collegium Pharmaceutical, Inc. to Host Earnings C..
AC
More news
Sector news : Pharmaceuticals - NEC
11:35aSANOFI'S VALPROATE RESTRICTED FOR SO : Regulator
DJ
10:32aSANOFI : UK bans Sanofi epilepsy drug without pregnancy prevention plan
RE
09:28aCircassia 2017 Pretax Loss Narrows; AstraZeneca Increases Stake
DJ
08:56aASTRAZENECA : Negative Results From Phase 3 Trial of Imfinzi and Tremelimumab
DJ
08:37aASTRAZENECA : to raise stake in Circassia to up to 19.9 percent
RE
More sector news : Pharmaceuticals - NEC
Latest Tweets
12:58a$COLL Pharmaceutical Inc 1 director sold: A director at Collegium Pharmaceut.. 
04/22Somewhat Positive Press Coverage Somewhat Unlikely to Affect Collegium Pharma.. 
04/20Collegium Pharmaceutical $COLL Upgraded to “Buy” at Zacks Investment Research.. 
04/19FY2019 EPS Estimates for Collegium Pharmaceutical $COLL Boosted by William Bl.. 
04/18Want the latest upgrades & downgrades for $JBL $COLL $PDVW $KMT $WLL? Che.. 
More tweets
Qtime:35
News from SeekingAlpha
03/27Depomed Distances Itself From Nucynta 
03/19Trump to release opioid epidemic plan 
03/16Key events next week - healthcare 
03/12COLLEGIUM : One Of The Few Winners In The Opioid Crisis 
03/08Premarket analyst action - healthcare (continued) 
Chart COLLEGIUM PHARMACEUTICAL I
Duration : Period :
Collegium Pharmaceutical I Technical Analysis Chart | COLL | US19459J1043 | 4-Traders
Technical analysis trends COLLEGIUM PHARMACEUTICAL I
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 31,8 $
Spread / Average Target 31%
EPS Revisions
Managers
NameTitle
Michael Thomas Heffernan Chairman, President & Chief Executive Officer
Joseph J. Ciaffoni Chief Operating Officer & Executive Vice President
Paul Brannelly CFO, Principal Accounting Officer & Executive VP
Alison Fleming Chief Technology Officer
Gino Santini Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
COLLEGIUM PHARMACEUTICAL INC31.15%815
JOHNSON & JOHNSON-9.23%339 783
PFIZER1.13%217 897
NOVARTIS-7.67%204 972
ROCHE HOLDING LTD.-12.52%192 109
MERCK AND COMPANY7.07%158 571